Zimmer-Biomet launches PrimaGen advanced bone allograft
Zimmer Biomet (NYSE:ZBH) said today it launched the PrimaGen advanced bone allograft designed as an allogeneic bone graft substitute for use in the repair, replacement, reconstruction or supplementation of tissue in muscuoloskeletal defects. The Warsaw, Ind.-based company said the PrimaGen advanced allograft contains the same bone healing elements as autografts while eliminating the risks associated with donor site morbidity or harvest site complications. “PrimaGen Advanced Allograft was developed to overcome the limitations of other bone graft substitutes and designed to offer a real alternative to autogra...
Source: Mass Device - December 14, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Orthopedics Zimmer Biomet Source Type: news

Zimmer Biomet Strengthens Spine Offering with PrimaGen Advanced(TM) Allograft
WARSAW, Ind., Dec. 13, 2016 -- (Healthcare Sales & Marketing Network) -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the launch of PrimaGen Advanced Allograft, an autograft substitute co... Devices, Orthopaedic, Product Launch Zimmer Biomet, PrimaGen, Advanced Allograft, Allograft (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2016 Category: Pharmaceuticals Source Type: news

Lab-grown bone shows 100% success rate in small, early study
Israel’s Bonus Biogroup (TLV:BONS) said today that it successfully injected its lab-grown, semi-liquid bone graft into the jaws of 11 people in an early stage clinical trial evaluating bone loss repair. The company is presenting its results at the International Conference on Oral & Maxillofacial Surgery in Spain today. The material is grown in a lab from a patient’s  own fat cells and then injected into the voids of problematic bones in the jaw. Over the course of a few months, the material hardens and merges with existing bones to fill out the jaw. The transplant “was 100% successful i...
Source: Mass Device - December 5, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Materials Testing Orthopedics Research & Development Stem Cells Bonus Biogroup Source Type: news

Xtant Medical wins FDA nod for Xsert lumbar implant
Xtant Medical (NYSE:XTNT) said today that it won 510(k) clearance from the FDA for its Xsert lumbar expandable interbody spine implant. The device is designed for lumbar fusion at 1 or 2 levels and is also cleared for use with autograft or autologous bone grafts including Belgrade, Mont.-based Xtant’s 3Demin and patented OsteoSponge allografts. “We are very pleased to have received clearance for Xsert. This system allows the surgeon to implant the cage in a tighter corridor and then expand the device according to the patient’s anatomy,” director Dr. David Kirschman said in prepared re...
Source: Mass Device - November 23, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Spinal Xtant Medical Source Type: news

Xtant Medical raises $4m, wins FDA nod for Irix-C cervical cage
Xtant Medical (NYSE:XTNT) said today it raised $3.8 million from a recent offering, and won FDA clearance for its Irix-C cervical cage. Subscriptions to the offering, offered at 75¢ per unit, ended yesterday. The Belgrade, Mont.-based company expects the offering to close completely on November 17, according to a press release. Xtant priced the offering earlier this month, looking to raise $11 million in the round. The company said it planned to float 15 million units at 75¢ per unit. Each unit in the round consists of 1 share of common stock and 1 warrant to purchase another share of stock. Xtant ...
Source: Mass Device - November 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Food & Drug Administration (FDA) Regulatory/Compliance Spinal Xtant Medical Source Type: news

Sinus Elevation: Are Bone Grafts Needed?
Would an implant placed after sinus elevation without a bone graft provide a satisfactory long-term outcome? (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - November 15, 2016 Category: Dentistry Authors: osseonews Tags: Implant News Regenerative Source Type: news

Efficacy of Epidermal Skin Grafts Over Complex Wounds Efficacy of Epidermal Skin Grafts Over Complex Wounds
Is epidermal skin grafting a safe and effective alternative to traditional autografts?Wounds (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 15, 2016 Category: Surgery Tags: General Surgery Journal Article Source Type: news

MassDevice.com +5 | The top 5 medtech stories for November 14, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Final FDA rules clarify adverse event reporting for contract manufacturers The FDA last week issued final guidance for medical device companies on the requirements for reporting adverse events that walked back much of the burde...
Source: Mass Device - November 14, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

LeMaitre Vascular pays $14m for Restore Flow Allografts
LeMaitre Vascular (NSDQ:LMAT) said last week that it agreed to put up $14 million for tissue preservation service provider Restore Flow Allografts. The deal calls for Burlington, Mass.-based LeMaitre to pay $12 million up front and another $2 million in May 2018, plus earn-puts pegged to sales performance over the next 2 years. Fox River Grove, Ill.-based Restore Flow, which offers human tissue preservation services for the processing and cryopreservation of peripheral vascular veins and arteries, posted break-even operating profits on sales of $3.7 million for the last 12 months, LeMaitre Vascular said...
Source: Mass Device - November 14, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Vascular Wall Street Beat LeMaitre Vascular Inc. Peripheral Artery Disease Restore Flow Allografts Source Type: news

Olympian D ’Agostino shares 3 lessons after ACL injury
“The crux of Olympic competition is to do everything you can to be the first one to cross the finish line,” says Abbey D’Agostino. But that’s not what Abbey did during the 5,000-meter qualifying heats in the 2016 summer games. Abbey had trained for her Olympic moment for years, adhering to the rigid 24/7 lifestyle of an elite athlete since graduating from Dartmouth College and signing to run professionally with New Balance. Abbey’s Olympic moment came unexpectedly when she and New Zealand runner Nikki Hamblin collided and tumbled to the ground. What happened at the Olympics is an example we sh...
Source: Thrive, Children's Hospital Boston - November 14, 2016 Category: Pediatrics Authors: Lisa Fratt Tags: Our Patients’ Stories ACL injury ACL tear Dr. Mininder Kocher Orthopedic Center Sports Medicine Source Type: news

BONESUPPORT(TM) Announces Key Corporate Appointment To Drive Growth In North America
LUND, Sweden, November 7, 2016 -- (Healthcare Sales & Marketing Network) -- BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone graft substitutes to treat bone voids caused by trauma, infection, disease or related surgery, is pleas... Devices, Orthopaedic, Personnel BONESUPPORT, CERAMENT, BONE VOID FILLER (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 7, 2016 Category: Pharmaceuticals Source Type: news

Wright Medical jumps on $240m hip settlement, Q3 results
Wright Medical (NSDQ:WMGI) shares are up nearly 4% today after the orthopedics company yesterday said it inked a $240 million settlement this month for nearly 1,300 product liability lawsuits brought over its metal-on-metal hip implants and released 3rd-quarter earnings that beat expectations on Wall Street. Wright, which lost an $11 million verdict in the 1st Conserve bellwether suit last year (the company is still litigating that decision), said it will pay $180 million in cash and cover the remaining $60 million with insurance. The deal covers about 85% of the claims lodged over Wright’s Conser...
Source: Mass Device - November 3, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: MassDevice Earnings Roundup Orthopedics Wall Street Beat Wright Medical N.V. Source Type: news

Ankle fusion or ankle replacement?
Treatment TermsAnkle pain and ankle injuryAnkle replacement surgeryOrthopaedics SEO Meta Description Ankle fusion and ankle replacement can relieve ankle pain and restore motion when nonsurgical treatments aren ’t effective. Author Karen Doss Bowman Sub-Title Choosing the right ankle surgery OverviewWhen persistent ankle arthritis from a chronic ankle injury or ankle fracture makes walking, exercise or climbing stairs unbearable, it’s time to consider your treatment options. Ankle fusion and ankle replacement can relieve ankle pain and restore motion when nonsurgical treatments aren’t effec...
Source: dukehealth.org: Duke Health News - November 1, 2016 Category: Consumer Health News Authors: dg62 at duke.edu Source Type: news

Amedica reduces workforce by 38%
Amedica (NSDQ:AMDA) said today it laid off approximately 38% of its workforce to lower operating expenses. The Salt Lake City, Utah-based company said the layoffs were part of a plan implemented on October 3 and completed the next day, which resulted in savings of approximately $2 million in annual cash operating expenses. The company said the action also incurred approximately $465,000 in one-time severance and related costs, which will be recorded in its 4th quarter of the 2016 fiscal year. “We acknowledge the hard work of those affected by this decision, towards bringing silicon nitride technology to patient ...
Source: Mass Device - October 5, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Amedica Source Type: news

Stryker launches Lite Bio bone graft delivery system
Stryker (NYSE:SYK) said today it is launching the Lite Bio bone graft material delivery system device designed for spinal surgeries. The company said the device allows for the use of preferred graft materials while allowing direct visualization of graft placement. The device can be operated signle-handed and used with any type of autograft, allograft or synthetic bone graft. “Our new Lite Bio delivery system is innovative in the marketplace, simplifying graft delivery for spine surgeons. Its sleek, versatile design can accommodate any bone graft material and provides surgeons with direct visualization to ai...
Source: Mass Device - October 4, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Spinal Stryker Source Type: news

For patients who need bone grafts, a 3D-printer could come to the rescue
Scientists have 3-D-printed splints for babies ’ airways, faux brains to study cortical folding — and now they’ve done it with bone. A team of researchers at Northwestern University has created a highly flexible artificial bone that helps speed up recovery and that can be easily manipulated by surgeons... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - September 28, 2016 Category: Science Authors: Amina Khan Source Type: news

Scientists fix fractures with 3D-printed synthetic bone
(Reuters) – Scientists in the United States have successfully treated broken spines and skulls in animals using 3D-printed synthetic bone, opening the possibility of future personalized bone implants for humans to fix dental, spinal other bone injuries. Unlike real bone grafts, the synthetic material – called hyper-elastic bone – is able to regenerate bone without the need for added growth factors, is flexible and strong, and can be easily and rapidly deployed in the operating room. Giving details in a teleconference, the scientists said the results of their animal trials – published on Wednesday i...
Source: Mass Device - September 28, 2016 Category: Medical Equipment Authors: MassDevice Tags: Orthopedics Research & Development Spinal Source Type: news

Are demineralized bone allografts (cortical or cancellous) fully bio-resorbable?
Have there been any conclusive studies to show whether or not allografts, particularly demineralized allografts, are fully bio-resorbable? (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - September 27, 2016 Category: Dentistry Authors: osseonews Tags: Clinical Questions Regenerative Source Type: news

NovaBone wins CE Mark for collagen-based dental wound dressings
Bio-active synthetic bone graft company NovaBone said today it won CE Mark approval in the European Union for its NovaTape and NovaPlug dental wound dressings. The Jacksonville, Fla.-based company said both devices are collagen-based and designed for the management of soft tissue oral wounds and sores, including dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites and surgical and traumatic wounds. “The CE mark approval is a major milestone for our company and a benefit to physicians and dentists in the European Union. NovaTape and NovaPlug are exceptionally user-friendly and ...
Source: Mass Device - September 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Dental Regulatory/Compliance Wound Care NovaBone Source Type: news

Spineology makes Musculoskeletal Transplant Foundation its sole allograft supplier
Spinal tech developer Spineology said today it expanded its relationship with the Muscoloskeletal Transplant Foundation, making it the sole tissue provider for its allograft product lines. The expanded deal will position MTF as the sole provider of tissue for Minneapolis-based Spineology’s new Incite cortigal fibers bone grafting solution. “MTF has a long track record of delivering safe, high quality tissue products using the most stringent standards in the industry. Our expanded relationship allows us to pass along that safety and quality to our customers,” CEO John Booth said in a prepared release. The ...
Source: Mass Device - September 23, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Regenerative Medicine Spinal Spineology Source Type: news

FDA clears Life Spine ’ s Pro-Link Ti cervical spacer
Life Spine said today that it won 510(k) clearance from the FDA for its Pro-Link Ti cervical spacer. The Huntley, Ill.-based company said the product is slated for full release by the end of 2016, joining a portfolio of devices that Life Spine launched this year. The spacers allow for the fusion of adjacent segments of spine without removing an existing anterior cervical plate. The locking plate provides security against screw backout, without disturbing the surrounding tissue, according to Life Spine. “Pro-Link Ti offers a low-profile, stand-alone cervical interbody with our groundbreaking Osseo-Loc technology. Osse...
Source: Mass Device - September 20, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Orthopedics Regulatory/Compliance Spinal Life Spine Source Type: news

Sunstar ’s GUIDOR® easy-graft® Alloplastic Bone Grafting System Now Available through Dental Dealers
Bone graft delivers easy handling and can eliminate the need for dental membrane SCHAUMBURG, ILLINOIS, June 10, 2016 — Sunstar Americas announced that it has expanded the purchasing options for its GUIDOR®easy-graft® Alloplastic Bone Grafting System by making it available through a network of 28 authorized U.S. dental dealers.Launched in late 2014 and capable of being syringed directly into a bone defect, GUIDOReasy-graftis the patented1bone grafting material that hardens into a stable, porous scaffold in minutes. Additionally, its ability to harden into a stable, porous scaffold allows clinicians to cho...
Source: Dental Technology Blog - September 20, 2016 Category: Dentistry Source Type: news

Bonesupport touts high infection eradication rate in prospective trial
Bonesupport today released data from the prospective trial of its Cerament G injectable antibiotic-eluting bone substitute, touting a 96% infection eradication rate in patients treated with the substitute. Data from the study was published in The Bone and Joint Journal, the company said. Cerament G is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis. The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months, while preventing colonization of microorganisms by eluting the antibiotic gentamicin. “The results th...
Source: Mass Device - September 1, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Orthopedics Bonesupport Source Type: news

FDA releases July 2016 510(k) clearances
510(K) SUMMARIES OR 510(K) STATEMENTS FOR FINAL DECISIONS RENDERED DURING THE PERIOD July 2016 TOTAL 510(k)s THIS PERIOD 236 TOTAL WITH SUMMARIES 220 TOTAL WITH STATEMENTS 16 DEVICE: Dakin's Skin and Wound Cleanser CENTURY PHARMACEUTICALS, INC. 510(k) NO: K150208(Traditional) ATTN: Stephen Deardorff PHONE NO : 1 317 8494210 10377 HAGUE RD. SE DECISION MADE: 21-JUL-16 INDIANAPOLIS IN 46256 510(k) SUMMARY AVAILABLE FROM FDA DEVICE: Sheath Introducer BIOTEQUE CORP. 510(k) NO: K150932(Traditional) ATTN: Simon Lin PHONE NO : 886 2 25710269 5 F-6, NO. 2...
Source: Mass Device - August 31, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Return to play following meniscus surgery - Brelin AM, Rue JP.
Meniscus tears are commonly encountered in the athletic population and can result in significant loss of playing time. Current treatment methods for acute tears consist of meniscectomy and meniscal repair, whereas meniscal allograft transplant is reserved ... (Source: SafetyLit)
Source: SafetyLit - August 27, 2016 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Amedica wins expanded FDA indication for Valeo II spinal fusion devices
Amedica (NSDQ:AMDA) said yesterday it won expanded FDA clearance for additional sizes of its Valeo II lateral lumbar interbody fusion device. The Valeo II lateral lumbar fusion device is made out of proprietary medical grade silicon nitride ceramic and includes 2nd-generation instrumentation for improved patient safety, the Salt Lake City, Utah-based company said. The device is indicated for intervertebral body fusion of the spine in skeletally mature patients with the use of an autograft to facilitate fusion, the company said. “I’m delighted to announce the recent FDA clearance of our expanded silicon nitride ...
Source: Mass Device - August 26, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Regulatory/Compliance Spinal Amedica Source Type: news

Derma Sciences touts Medicare reimbursement win
Derma Sciences (NSDQ:DSCI) said yesterday that Medicare Administrative Contractor National Government Services will now consider the company’s Amnioexcel amniotic allograft membrane for coverage. The change comes as NGS, which serves states in the Northeast and Midwest, sets to retire its local coverage determination for cellular or tissue based products as of September 1st. The change will allow Derma Sciences’ Amnioexcel to be considered with appropriate documentation of medical necessity as a second-line therapy, following standard wound care treatment. “We are very pleased wit...
Source: Mass Device - August 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Medicare Regenerative Medicine Derma Sciences Inc. Source Type: news

Derma Sciences, Organogenesis tout Medicare reimbursement win
Updated to include more information, commentary from Organogenesis. Medicare administrative contractor National Government Services has retired previous coverage policies on cellular and tissue-based products, effective September 1st. The change will allow new coverages and reimbursement through Medicare for such products based on FDA labeling and packaging. Derma Sciences (NSDQ:DSCI and Organogenesis have said the changes will allow for their products to receive coverage and reimbursement for individuals covered under NGS. Approximately 24 million Medicare Part B beneficiaries are covered by NGS, ...
Source: Mass Device - August 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Medicare Regenerative Medicine Derma Sciences Inc. Source Type: news

Pregnancy After Kidney Transplant and Allograft Failure Risk Pregnancy After Kidney Transplant and Allograft Failure Risk
Delaying pregnancy after kidney transplantation may decrease the risk of allograft failure. What is the optimal timing?American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Osteovation Bone Graft Cement in Sinus Lift Procedure?
 I was thinking of using Osteovation a calcium phosphate bone cement for the graft.   (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - August 23, 2016 Category: Dentistry Authors: osseonews Tags: Clinical Questions Regenerative Source Type: news

Return to play of rugby players after anterior cruciate ligament reconstruction using hamstring autograft: return to sports and graft failure according to age - Takazawa Y, Ikeda H, Saita Y, Kawasaki T, Ishijima M, Nagayama M, Kaneko H, Kaneko K.
PURPOSE: To assess return to play and the frequencies of graft failure in rugby players after anterior cruciate ligament (ACL) reconstruction using a hamstring autograft augmented with an artificial ligament and to compare outcomes between rugby players ag... (Source: SafetyLit)
Source: SafetyLit - August 20, 2016 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Bone graft quality?
I would like input on the bone graft quality. I see a kind of a void above the new bone below the sinus. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - August 17, 2016 Category: Dentistry Authors: osseonews Tags: Clinical Cases Regenerative Source Type: news

MassDevice.com +5 | The top 5 medtech stories for August 12, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Bonesupport wins FDA nod for Cerament G trial Bonesupport said it won an investigational device exemption for the Fortify clinical trial of its next-generation Cerament G injectable antibiotic-eluting bone substitute. Cerament ...
Source: Mass Device - August 12, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Bonesupport wins FDA nod for Cerament G trial
Bonesupport said it won an investigational device exemption for the Fortify clinical trial of its next-generation Cerament G injectable antibiotic-eluting bone substitute. Cerament G product is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis. The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months, while preventing colonization of microorganisms by eluting the antibiotic gentamicin. Bonesupport said Cerament G, which won CE Mark approval in the European Union back in February 2013, is on the mark...
Source: Mass Device - August 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Orthopedics Regulatory/Compliance Source Type: news

Derma Sciences closes $80m deal for BioD
Derma Sciences (NSDQ:DSCI) said yesterday that it closed its acquisition of regenerative allograft maker BioD in a deal worth up to $78 million, including milestones and earn-outs. Princeton, N.J.-based Derma Sciences said it paid $21.3 million up front in a mix of cash and stock; meeting regulatory milestones could mean another $30 million, and the transaction included $26.5 million in earn-outs pegged to net sales growth. The deal, announced July 28, closed August 5, the company said in a regulatory filing. BioD makes a line of allograft products derived from human placental tissue, includin...
Source: Mass Device - August 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Regenerative Medicine Wound Care BioD Derma Sciences Inc. Source Type: news

Bilirubin contributes to immune suppression after islet transplants
(Cell Transplantation Center of Excellence for Aging and Brain Repair) Stress and injury can cause up to a 70 percent loss of transplanted islet cells within 72 hours after transplantation. Bilirubin, an antioxidant, was used successfully as a supplement to suppress the immune response to allograft islet transplantation and also significantly decrease islet cell death after the cells had been isolated and undergone nutrient deprivation and hypoxic (low oxygen) stress. Bilirubin supplementation could improve outcomes after allograft islet cell transplantation to treat type 1 diabetes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 11, 2016 Category: Biology Source Type: news

Spine Wave launches Velocity expandable lateral spine implant
Spine Wave said today it is launching its Velocity L expandable interbody device and XLR II lateral access system, both of which are designed for lateral surgical approaches for spinal procedures. The expandable device is designed to minimize impaction of large lateral implants into collapsed disk spaces through a slim profile which expands to the desired disc space height, the Shelton, Conn.-based company said. “The Velocity L is the culmination of a multiyear effort to develop an implant that embodies all the characteristics surgeons desire in a lateral expandable interbody device. We believe that th...
Source: Mass Device - August 11, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Spinal Surgical Spine Wave Source Type: news

Amnion/Chorion Membrane Allograft for Diabetic Foot Ulcers Amnion/Chorion Membrane Allograft for Diabetic Foot Ulcers
These cases highlight the use and efficacy of micronized dehydrated human amnion/chorion membrane allografts in patients with diabetic foot ulcers.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Wright Medical surges on Street-beating Q2
Wright Medical (NSDQ:WMGI) saw shares surge over 10% after releasing 2nd quarter earnings that topped the Street in earnings per share but were off on revenue. The Memphis, Tenn.-based company reported losses of $229.4 million, or $2.23 per share, on sales of $170.7 million for the 3 months ended June 26. That amounts to an over 400% increase in losses while sales grew over 100% compared with the same period in 2015. After adjusting to exclude 1-time items, losses per share were 11¢, half of the 22¢ losses per share The Street expected to see for the quarter. The Street’s revenue expectations of $219.7 mill...
Source: Mass Device - August 3, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wright Medical Group Inc. Source Type: news

BioVentus delays $150m IPO
Orthobiologics maker Bioventus postponed its initial public offering which was slated to raise up to $150 million for the company, according to Renaissance Capital. The company plans to float 8.8 million shares at a price range of between $16 and $18, and plans to list on the NASDAQ Global Market under the ticker “BIOV”. The initial public offering was scheduled to open today, according to Renaissance Capital, and the company has yet to announce a new date. At the midpoint of its proposed range, the company would command a fully diluted market value of $566 million, and proceeds from the round should gener...
Source: Mass Device - July 29, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Orthopedics Regenerative Medicine Bioventus LLC Source Type: news

Human Skin Allograft for Wounds With Exposed Tendon or Bone Human Skin Allograft for Wounds With Exposed Tendon or Bone
Cryopreserved skin allografts may be a safe and effective option for treating wounds with exposed bone or tendon. Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2016 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

Orthofix wins Japanese regulatory win for Phoenix spinal fixation system
Orthofix (NSDQ:OFIX) said today it won regulatory approval from the Japanese Ministry of Health, Labor and Wellfare for its Phoenix minimally invasive spinal fixation system. The Phoenix system allows for the percutaneous placement of pedicle screws designed to provide stabilization and correction for spinal fusion patients suffering from degenerative disc disease and other conditions, the company said. “The Japanese approval and full market launch of the Phoenix MIS fixation system represents an important step towards broadening the availability of our spine fixation products globally by entering the 2nd l...
Source: Mass Device - July 28, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Regulatory/Compliance Spinal Orthofix International Source Type: news

My Participatory Medicine Story: Osteonecrosis / Avascular Necrosis
My name is Alexandra Albin (msaxolotl on Twitter) and I have an orthopedic condition called osteonecrosis or avascular necrosis (AVN). AVN is a painful and debilitating bone disease that typically affects long bones, is caused by a loss of blood supply to the bone, and can lead to bone degeneration and the collapse of joint surfaces. AVN can happen for many reasons. In my case it was the result of medications — steroids —given for a misdiagnosed condition of Multiple Sclerosis (MS) in 1994. That was my third strange neurological episode over several years of what was suspected to be MS, but never confirmed. One...
Source: Society for Participatory Medicine - July 28, 2016 Category: Journals (General) Authors: Mayank Agarwal Tags: Member Updates Newsletter Alexandra Albin AVN CEO of my own body osteonecrosis paralyzed baldder participatory medicine vascular Necrosis Source Type: news

Orthofix touts high fusion rates in Trinity Evolution study
This study demonstrated the effectiveness of Trinity Evolution in achieving a solid fusion when used in this manner, indicating that it is a viable option for patients needing anterior cervical discectomy and fusion,” co-author Dr. Timothy Peppers of Scripps Hospital said in a prepared statement. Orthofix reported significantly improved neck function and neck/arm pain at 6 and 12 months, with no serious adverse events related to the Trinity Evolution. Fusion rates were 78.6% at 6 months and 93.5% after 12 months. “MTF is committed to research to ensure innovative clinical options exist for all patients. We are ...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Regenerative Medicine Spinal Orthofix International Source Type: news

Bioventus sets terms on $150m IPO
Orthobiologics maker Bioventus today released terms for its $150 million initial public offering, looking to float 8.8 million shares at between $16 and $18 per share, with plans to list on the NASDAQ Global Market under the ticker “BIOV”. At the midpoint of its proposed range, the company would command a fully diluted market value of $566 million, and proceeds from the round should generate between $141 and $159 million, according to an SEC filing from the company. The company originally announced plans for the IPO earlier this month, planning to use proceeds from the round to pay off its debt. Durha...
Source: Mass Device - July 19, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Bioventus LLC Smith & Nephew Source Type: news

Does Osteochondral Allograft Transplant Keep Athletes From Sport?Does Osteochondral Allograft Transplant Keep Athletes From Sport?
Athletes who undergo a transplantation of osteochondral tissue from a cadaver to repair a knee may return to sport at a rate of 76%, a new study suggests. Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - July 12, 2016 Category: Orthopaedics Tags: Orthopaedics News Source Type: news

Saving Knees with Allograft
CHICAGO. (Ivanhoe Newswire) -- More than one-third of all Americans report being affected by knee pain. Knee replacement surgery can offer relief, but the implants only last between 12 and 15 years. Patients under the age of 40 aren’t usually considered good candidates for the procedure because they would need too many revision operations. Now there’s a simple surgery that’s saving knees in younger patients. (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - July 11, 2016 Category: Consumer Health News Source Type: news

Osteochondral allograft transplantation effective for treating knee cartilage injuries
For athletes and highly active patients who sustain cartilage injuries to their knee, an osteochondral allograft transplantation can be a successful treatment option, according to new research. The study showed these patients were consistently able to return to sport or recreational activities after the surgery, though frequently at a lower activity level. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 10, 2016 Category: Science Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 1, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Nestle poaches Fresenius CEO Schneider Nestle lured the CEO of Fresenius, Ulf Mark Schneider, to the corner office this week. Fresenius promoted CFO Stephan Sturm to replace Schneider. Read more   4. Biotronik wins...
Source: Mass Device - July 1, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Bioventus files for $150m IPO
Orthobiologics maker Bioventus yesterday registered for an initial public offering it plans to use to pay off debt. Durham, N.C.-based Bioventus was formed in 2012 when Smith & Nephew (NYSE:SNN) spun out its biologics and clinical therapies division in a joint venture with venture capital firm Essex Woodlands. In October 2014 Bioventus acquired the OsteoAMP product line from Advanced Biologics for an undisclosed amount; late last year the company added BioStructures, a developer of absorbable bone grafts, also for an undisclosed amount. In January Bioventus named former Medtronic (NYSE:MDT...
Source: Mass Device - July 1, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Orthopedics Regenerative Medicine Bioventus LLC Source Type: news